Global TMJ Disorders Market

TMJ Disorders Comprehensive Study by Type (Muscular, Structural, Acute), Treatment (-Nonsurgical Treatments, Mouth Guards, Physical Therapy, Trigger Point Injections, Others, -Surgery, Arthrocentesis, TMJ arthroscopy, Open Joint Surgery), End User (Hospitals & Clinics, Ambulatory Surgery Centre, Academic Institute, Others) Players and Region - Global Market Outlook to 2028

TMJ Disorders Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 3.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About TMJ Disorders
The Temporomandibular joints (TMJ) are the two joints that connect your lower jaw to your skull. Temporomandibular disorders of the jaw muscles, temporomandibular joints, and the nerves associated with chronic facial pain. Any problem that prevents the complex system of muscles, bones and joints from working together in harmony may result in temporomandibular disorder. The disorder may be intra articular, due to inflammation, internal structure changes or degeneration, commonly the muscle of mastication or the cervical muscles.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
CAGR3.7%


TMJ Disorders is highly competitive, with several key players dominating the industry. The market players are focused on developing a variety of features and benefits to meet the needs. Thus, constantly introducing new innovation in processing to meet the changing needs and preferences of consumers. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global TMJ Disorders market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Zydus Candila (India), Novartis International AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Ltd. (Israel), Allergan (Ireland), Jubilant Life Science Limited (India), Mylan NV (United States), Abbott Laboratories (United States), Bayer AG (Germany) and Bristol Myers Squibb (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are AbbVie Inc. (United States), Pfizer Inc. (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global TMJ Disorders market by Type (Muscular, Structural and Acute) and Region.



On the basis of geography, the market of TMJ Disorders has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. -Nonsurgical Treatments will boost the TMJ Disorders market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals & Clinics will boost the TMJ Disorders market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising prevalence and awareness of TMJ disorders. and Growing demand for minimally invasive treatments.

Market Growth Drivers:
Growing adoption of multidisciplinary treatment approach. and Expanding geriatric population.

Challenges:
Sleep disturbance and impact on overall sleep quality. and Difficulty in diagnosing TMJ disorder accurately.

Restraints:
High treatment cost., Lack of awareness among the general population. and Poorly understood ethology of TMJ disorder.

Opportunities:
Growing healthcare infrastructure. and Technological advancement in diagnostic imaging.

Market Leaders and their expansionary development strategies
In December 2023, Drugmaker AbbVie, intends to focus on smaller deals to support its growth through next decade, after it struck two multibillion dollar deals in the past week to acquired Cerevel Therapeutics and ImmunoGen. AbbVie is in a stronger position to deliver sustainable long term performance.
In September 2023, Laser technology has paved the way for precise and efficient TMJ/TMD treatment. Dental lasers can alleviate pain, reduce inflammation, and promote tissues regeneration in the jaw joint area. Laser therapy is gentle, minimally invasive, and allows for quicker healing and recovery times.


Key Target Audience
Research and Developers, Investors, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Muscular
  • Structural
  • Acute
By Treatment
  • -Nonsurgical Treatments
  • Mouth Guards
  • Physical Therapy
  • Trigger Point Injections
  • Others
  • -Surgery
  • Arthrocentesis
  • TMJ arthroscopy
  • Open Joint Surgery

By End User
  • Hospitals & Clinics
  • Ambulatory Surgery Centre
  • Academic Institute
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing adoption of multidisciplinary treatment approach.
      • 3.2.2. Expanding geriatric population.
    • 3.3. Market Challenges
      • 3.3.1. Sleep disturbance and impact on overall sleep quality.
      • 3.3.2. Difficulty in diagnosing TMJ disorder accurately.
    • 3.4. Market Trends
      • 3.4.1. Rising prevalence and awareness of TMJ disorders.
      • 3.4.2. Growing demand for minimally invasive treatments.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global TMJ Disorders, by Type, Treatment, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global TMJ Disorders (Value)
      • 5.2.1. Global TMJ Disorders by: Type (Value)
        • 5.2.1.1. Muscular
        • 5.2.1.2. Structural
        • 5.2.1.3. Acute
      • 5.2.2. Global TMJ Disorders by: Treatment (Value)
        • 5.2.2.1. -Nonsurgical Treatments
        • 5.2.2.2. Mouth Guards
        • 5.2.2.3. Physical Therapy
        • 5.2.2.4. Trigger Point Injections
        • 5.2.2.5. Others
        • 5.2.2.6. -Surgery
        • 5.2.2.7. Arthrocentesis
        • 5.2.2.8. TMJ arthroscopy
        • 5.2.2.9. Open Joint Surgery
      • 5.2.3. Global TMJ Disorders by: End User (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Ambulatory Surgery Centre
        • 5.2.3.3. Academic Institute
        • 5.2.3.4. Others
      • 5.2.4. Global TMJ Disorders Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. TMJ Disorders: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Zydus Candila (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Jubilant Life Science Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan NV (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global TMJ Disorders Sale, by Type, Treatment, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global TMJ Disorders (Value)
      • 7.2.1. Global TMJ Disorders by: Type (Value)
        • 7.2.1.1. Muscular
        • 7.2.1.2. Structural
        • 7.2.1.3. Acute
      • 7.2.2. Global TMJ Disorders by: Treatment (Value)
        • 7.2.2.1. -Nonsurgical Treatments
        • 7.2.2.2. Mouth Guards
        • 7.2.2.3. Physical Therapy
        • 7.2.2.4. Trigger Point Injections
        • 7.2.2.5. Others
        • 7.2.2.6. -Surgery
        • 7.2.2.7. Arthrocentesis
        • 7.2.2.8. TMJ arthroscopy
        • 7.2.2.9. Open Joint Surgery
      • 7.2.3. Global TMJ Disorders by: End User (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Ambulatory Surgery Centre
        • 7.2.3.3. Academic Institute
        • 7.2.3.4. Others
      • 7.2.4. Global TMJ Disorders Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. TMJ Disorders: by Type(USD Million)
  • Table 2. TMJ Disorders Muscular , by Region USD Million (2017-2022)
  • Table 3. TMJ Disorders Structural , by Region USD Million (2017-2022)
  • Table 4. TMJ Disorders Acute , by Region USD Million (2017-2022)
  • Table 5. TMJ Disorders: by Treatment(USD Million)
  • Table 6. TMJ Disorders -Nonsurgical Treatments , by Region USD Million (2017-2022)
  • Table 7. TMJ Disorders Mouth Guards , by Region USD Million (2017-2022)
  • Table 8. TMJ Disorders Physical Therapy , by Region USD Million (2017-2022)
  • Table 9. TMJ Disorders Trigger Point Injections , by Region USD Million (2017-2022)
  • Table 10. TMJ Disorders Others , by Region USD Million (2017-2022)
  • Table 11. TMJ Disorders -Surgery , by Region USD Million (2017-2022)
  • Table 12. TMJ Disorders Arthrocentesis , by Region USD Million (2017-2022)
  • Table 13. TMJ Disorders TMJ arthroscopy , by Region USD Million (2017-2022)
  • Table 14. TMJ Disorders Open Joint Surgery , by Region USD Million (2017-2022)
  • Table 15. TMJ Disorders: by End User(USD Million)
  • Table 16. TMJ Disorders Hospitals & Clinics , by Region USD Million (2017-2022)
  • Table 17. TMJ Disorders Ambulatory Surgery Centre , by Region USD Million (2017-2022)
  • Table 18. TMJ Disorders Academic Institute , by Region USD Million (2017-2022)
  • Table 19. TMJ Disorders Others , by Region USD Million (2017-2022)
  • Table 20. South America TMJ Disorders, by Country USD Million (2017-2022)
  • Table 21. South America TMJ Disorders, by Type USD Million (2017-2022)
  • Table 22. South America TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 23. South America TMJ Disorders, by End User USD Million (2017-2022)
  • Table 24. Brazil TMJ Disorders, by Type USD Million (2017-2022)
  • Table 25. Brazil TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 26. Brazil TMJ Disorders, by End User USD Million (2017-2022)
  • Table 27. Argentina TMJ Disorders, by Type USD Million (2017-2022)
  • Table 28. Argentina TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 29. Argentina TMJ Disorders, by End User USD Million (2017-2022)
  • Table 30. Rest of South America TMJ Disorders, by Type USD Million (2017-2022)
  • Table 31. Rest of South America TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 32. Rest of South America TMJ Disorders, by End User USD Million (2017-2022)
  • Table 33. Asia Pacific TMJ Disorders, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific TMJ Disorders, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 36. Asia Pacific TMJ Disorders, by End User USD Million (2017-2022)
  • Table 37. China TMJ Disorders, by Type USD Million (2017-2022)
  • Table 38. China TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 39. China TMJ Disorders, by End User USD Million (2017-2022)
  • Table 40. Japan TMJ Disorders, by Type USD Million (2017-2022)
  • Table 41. Japan TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 42. Japan TMJ Disorders, by End User USD Million (2017-2022)
  • Table 43. India TMJ Disorders, by Type USD Million (2017-2022)
  • Table 44. India TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 45. India TMJ Disorders, by End User USD Million (2017-2022)
  • Table 46. South Korea TMJ Disorders, by Type USD Million (2017-2022)
  • Table 47. South Korea TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 48. South Korea TMJ Disorders, by End User USD Million (2017-2022)
  • Table 49. Taiwan TMJ Disorders, by Type USD Million (2017-2022)
  • Table 50. Taiwan TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 51. Taiwan TMJ Disorders, by End User USD Million (2017-2022)
  • Table 52. Australia TMJ Disorders, by Type USD Million (2017-2022)
  • Table 53. Australia TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 54. Australia TMJ Disorders, by End User USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific TMJ Disorders, by Type USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 57. Rest of Asia-Pacific TMJ Disorders, by End User USD Million (2017-2022)
  • Table 58. Europe TMJ Disorders, by Country USD Million (2017-2022)
  • Table 59. Europe TMJ Disorders, by Type USD Million (2017-2022)
  • Table 60. Europe TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 61. Europe TMJ Disorders, by End User USD Million (2017-2022)
  • Table 62. Germany TMJ Disorders, by Type USD Million (2017-2022)
  • Table 63. Germany TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 64. Germany TMJ Disorders, by End User USD Million (2017-2022)
  • Table 65. France TMJ Disorders, by Type USD Million (2017-2022)
  • Table 66. France TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 67. France TMJ Disorders, by End User USD Million (2017-2022)
  • Table 68. Italy TMJ Disorders, by Type USD Million (2017-2022)
  • Table 69. Italy TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 70. Italy TMJ Disorders, by End User USD Million (2017-2022)
  • Table 71. United Kingdom TMJ Disorders, by Type USD Million (2017-2022)
  • Table 72. United Kingdom TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 73. United Kingdom TMJ Disorders, by End User USD Million (2017-2022)
  • Table 74. Netherlands TMJ Disorders, by Type USD Million (2017-2022)
  • Table 75. Netherlands TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 76. Netherlands TMJ Disorders, by End User USD Million (2017-2022)
  • Table 77. Rest of Europe TMJ Disorders, by Type USD Million (2017-2022)
  • Table 78. Rest of Europe TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 79. Rest of Europe TMJ Disorders, by End User USD Million (2017-2022)
  • Table 80. MEA TMJ Disorders, by Country USD Million (2017-2022)
  • Table 81. MEA TMJ Disorders, by Type USD Million (2017-2022)
  • Table 82. MEA TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 83. MEA TMJ Disorders, by End User USD Million (2017-2022)
  • Table 84. Middle East TMJ Disorders, by Type USD Million (2017-2022)
  • Table 85. Middle East TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 86. Middle East TMJ Disorders, by End User USD Million (2017-2022)
  • Table 87. Africa TMJ Disorders, by Type USD Million (2017-2022)
  • Table 88. Africa TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 89. Africa TMJ Disorders, by End User USD Million (2017-2022)
  • Table 90. North America TMJ Disorders, by Country USD Million (2017-2022)
  • Table 91. North America TMJ Disorders, by Type USD Million (2017-2022)
  • Table 92. North America TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 93. North America TMJ Disorders, by End User USD Million (2017-2022)
  • Table 94. United States TMJ Disorders, by Type USD Million (2017-2022)
  • Table 95. United States TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 96. United States TMJ Disorders, by End User USD Million (2017-2022)
  • Table 97. Canada TMJ Disorders, by Type USD Million (2017-2022)
  • Table 98. Canada TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 99. Canada TMJ Disorders, by End User USD Million (2017-2022)
  • Table 100. Mexico TMJ Disorders, by Type USD Million (2017-2022)
  • Table 101. Mexico TMJ Disorders, by Treatment USD Million (2017-2022)
  • Table 102. Mexico TMJ Disorders, by End User USD Million (2017-2022)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. TMJ Disorders: by Type(USD Million)
  • Table 114. TMJ Disorders Muscular , by Region USD Million (2023-2028)
  • Table 115. TMJ Disorders Structural , by Region USD Million (2023-2028)
  • Table 116. TMJ Disorders Acute , by Region USD Million (2023-2028)
  • Table 117. TMJ Disorders: by Treatment(USD Million)
  • Table 118. TMJ Disorders -Nonsurgical Treatments , by Region USD Million (2023-2028)
  • Table 119. TMJ Disorders Mouth Guards , by Region USD Million (2023-2028)
  • Table 120. TMJ Disorders Physical Therapy , by Region USD Million (2023-2028)
  • Table 121. TMJ Disorders Trigger Point Injections , by Region USD Million (2023-2028)
  • Table 122. TMJ Disorders Others , by Region USD Million (2023-2028)
  • Table 123. TMJ Disorders -Surgery , by Region USD Million (2023-2028)
  • Table 124. TMJ Disorders Arthrocentesis , by Region USD Million (2023-2028)
  • Table 125. TMJ Disorders TMJ arthroscopy , by Region USD Million (2023-2028)
  • Table 126. TMJ Disorders Open Joint Surgery , by Region USD Million (2023-2028)
  • Table 127. TMJ Disorders: by End User(USD Million)
  • Table 128. TMJ Disorders Hospitals & Clinics , by Region USD Million (2023-2028)
  • Table 129. TMJ Disorders Ambulatory Surgery Centre , by Region USD Million (2023-2028)
  • Table 130. TMJ Disorders Academic Institute , by Region USD Million (2023-2028)
  • Table 131. TMJ Disorders Others , by Region USD Million (2023-2028)
  • Table 132. South America TMJ Disorders, by Country USD Million (2023-2028)
  • Table 133. South America TMJ Disorders, by Type USD Million (2023-2028)
  • Table 134. South America TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 135. South America TMJ Disorders, by End User USD Million (2023-2028)
  • Table 136. Brazil TMJ Disorders, by Type USD Million (2023-2028)
  • Table 137. Brazil TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 138. Brazil TMJ Disorders, by End User USD Million (2023-2028)
  • Table 139. Argentina TMJ Disorders, by Type USD Million (2023-2028)
  • Table 140. Argentina TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 141. Argentina TMJ Disorders, by End User USD Million (2023-2028)
  • Table 142. Rest of South America TMJ Disorders, by Type USD Million (2023-2028)
  • Table 143. Rest of South America TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 144. Rest of South America TMJ Disorders, by End User USD Million (2023-2028)
  • Table 145. Asia Pacific TMJ Disorders, by Country USD Million (2023-2028)
  • Table 146. Asia Pacific TMJ Disorders, by Type USD Million (2023-2028)
  • Table 147. Asia Pacific TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 148. Asia Pacific TMJ Disorders, by End User USD Million (2023-2028)
  • Table 149. China TMJ Disorders, by Type USD Million (2023-2028)
  • Table 150. China TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 151. China TMJ Disorders, by End User USD Million (2023-2028)
  • Table 152. Japan TMJ Disorders, by Type USD Million (2023-2028)
  • Table 153. Japan TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 154. Japan TMJ Disorders, by End User USD Million (2023-2028)
  • Table 155. India TMJ Disorders, by Type USD Million (2023-2028)
  • Table 156. India TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 157. India TMJ Disorders, by End User USD Million (2023-2028)
  • Table 158. South Korea TMJ Disorders, by Type USD Million (2023-2028)
  • Table 159. South Korea TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 160. South Korea TMJ Disorders, by End User USD Million (2023-2028)
  • Table 161. Taiwan TMJ Disorders, by Type USD Million (2023-2028)
  • Table 162. Taiwan TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 163. Taiwan TMJ Disorders, by End User USD Million (2023-2028)
  • Table 164. Australia TMJ Disorders, by Type USD Million (2023-2028)
  • Table 165. Australia TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 166. Australia TMJ Disorders, by End User USD Million (2023-2028)
  • Table 167. Rest of Asia-Pacific TMJ Disorders, by Type USD Million (2023-2028)
  • Table 168. Rest of Asia-Pacific TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 169. Rest of Asia-Pacific TMJ Disorders, by End User USD Million (2023-2028)
  • Table 170. Europe TMJ Disorders, by Country USD Million (2023-2028)
  • Table 171. Europe TMJ Disorders, by Type USD Million (2023-2028)
  • Table 172. Europe TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 173. Europe TMJ Disorders, by End User USD Million (2023-2028)
  • Table 174. Germany TMJ Disorders, by Type USD Million (2023-2028)
  • Table 175. Germany TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 176. Germany TMJ Disorders, by End User USD Million (2023-2028)
  • Table 177. France TMJ Disorders, by Type USD Million (2023-2028)
  • Table 178. France TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 179. France TMJ Disorders, by End User USD Million (2023-2028)
  • Table 180. Italy TMJ Disorders, by Type USD Million (2023-2028)
  • Table 181. Italy TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 182. Italy TMJ Disorders, by End User USD Million (2023-2028)
  • Table 183. United Kingdom TMJ Disorders, by Type USD Million (2023-2028)
  • Table 184. United Kingdom TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 185. United Kingdom TMJ Disorders, by End User USD Million (2023-2028)
  • Table 186. Netherlands TMJ Disorders, by Type USD Million (2023-2028)
  • Table 187. Netherlands TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 188. Netherlands TMJ Disorders, by End User USD Million (2023-2028)
  • Table 189. Rest of Europe TMJ Disorders, by Type USD Million (2023-2028)
  • Table 190. Rest of Europe TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 191. Rest of Europe TMJ Disorders, by End User USD Million (2023-2028)
  • Table 192. MEA TMJ Disorders, by Country USD Million (2023-2028)
  • Table 193. MEA TMJ Disorders, by Type USD Million (2023-2028)
  • Table 194. MEA TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 195. MEA TMJ Disorders, by End User USD Million (2023-2028)
  • Table 196. Middle East TMJ Disorders, by Type USD Million (2023-2028)
  • Table 197. Middle East TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 198. Middle East TMJ Disorders, by End User USD Million (2023-2028)
  • Table 199. Africa TMJ Disorders, by Type USD Million (2023-2028)
  • Table 200. Africa TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 201. Africa TMJ Disorders, by End User USD Million (2023-2028)
  • Table 202. North America TMJ Disorders, by Country USD Million (2023-2028)
  • Table 203. North America TMJ Disorders, by Type USD Million (2023-2028)
  • Table 204. North America TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 205. North America TMJ Disorders, by End User USD Million (2023-2028)
  • Table 206. United States TMJ Disorders, by Type USD Million (2023-2028)
  • Table 207. United States TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 208. United States TMJ Disorders, by End User USD Million (2023-2028)
  • Table 209. Canada TMJ Disorders, by Type USD Million (2023-2028)
  • Table 210. Canada TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 211. Canada TMJ Disorders, by End User USD Million (2023-2028)
  • Table 212. Mexico TMJ Disorders, by Type USD Million (2023-2028)
  • Table 213. Mexico TMJ Disorders, by Treatment USD Million (2023-2028)
  • Table 214. Mexico TMJ Disorders, by End User USD Million (2023-2028)
  • Table 215. Research Programs/Design for This Report
  • Table 216. Key Data Information from Secondary Sources
  • Table 217. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global TMJ Disorders: by Type USD Million (2017-2022)
  • Figure 5. Global TMJ Disorders: by Treatment USD Million (2017-2022)
  • Figure 6. Global TMJ Disorders: by End User USD Million (2017-2022)
  • Figure 7. South America TMJ Disorders Share (%), by Country
  • Figure 8. Asia Pacific TMJ Disorders Share (%), by Country
  • Figure 9. Europe TMJ Disorders Share (%), by Country
  • Figure 10. MEA TMJ Disorders Share (%), by Country
  • Figure 11. North America TMJ Disorders Share (%), by Country
  • Figure 12. Global TMJ Disorders share by Players 2022 (%)
  • Figure 13. Global TMJ Disorders share by Players (Top 3) 2022(%)
  • Figure 14. Global TMJ Disorders share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Zydus Candila (India) Revenue, Net Income and Gross profit
  • Figure 17. Zydus Candila (India) Revenue: by Geography 2022
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 20. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 21. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 22. Teva Pharmaceutical Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Teva Pharmaceutical Ltd. (Israel) Revenue: by Geography 2022
  • Figure 24. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Allergan (Ireland) Revenue: by Geography 2022
  • Figure 26. Jubilant Life Science Limited (India) Revenue, Net Income and Gross profit
  • Figure 27. Jubilant Life Science Limited (India) Revenue: by Geography 2022
  • Figure 28. Mylan NV (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan NV (United States) Revenue: by Geography 2022
  • Figure 30. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 32. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 34. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 36. Global TMJ Disorders: by Type USD Million (2023-2028)
  • Figure 37. Global TMJ Disorders: by Treatment USD Million (2023-2028)
  • Figure 38. Global TMJ Disorders: by End User USD Million (2023-2028)
  • Figure 39. South America TMJ Disorders Share (%), by Country
  • Figure 40. Asia Pacific TMJ Disorders Share (%), by Country
  • Figure 41. Europe TMJ Disorders Share (%), by Country
  • Figure 42. MEA TMJ Disorders Share (%), by Country
  • Figure 43. North America TMJ Disorders Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Zydus Candila (India)
  • Novartis International AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Ltd. (Israel)
  • Allergan (Ireland)
  • Jubilant Life Science Limited (India)
  • Mylan NV (United States)
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Bristol Myers Squibb (United States)
Additional players considered in the study are as follows:
AbbVie Inc. (United States) , Pfizer Inc. (United States) , Others
Select User Access Type

Key Highlights of Report


Jan 2024 247 Pages 62 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global TMJ Disorders Market Quantitative research analysis
Global TMJ Disorders Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Zydus Candila (India), Novartis International AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Ltd. (Israel), Allergan (Ireland), Jubilant Life Science Limited (India), Mylan NV (United States), Abbott Laboratories (United States), Bayer AG (Germany) and Bristol Myers Squibb (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising prevalence and awareness of TMJ disorders. " is seen as one of major influencing trends for TMJ Disorders Market during projected period 2022-2028.
The TMJ Disorders market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates TMJ Disorders Market to reach USD920.0 Million by 2028.

Know More About Global TMJ Disorders Market Report?

Have a Query? Click Here

Other Related Reports

Hallux Rigidus Comprehensive Study by Treatment (-Non-Surgical Treatment, Shoe Modification, Orthotic Devices, Medications, Injection Therapy, Physical Therapy, -Surgical Treatment, Bone Spur Removal...
$ 3800
Teledermatology Comprehensive Study by Application (Direct consultations, Specialist referral, Online patient triage, Virtual prescription renewals, Patient follow-up care), Type (Synchronous, Asynch...
$ 3800
Retinal Detachment- Comprehensive Study by Type (Rhegmatogenous, Tractional, Exudative), Treatment Type (Surgical Others, Laser Therapy, Cryopexy, Others), End User (Hospitals, Speciality centre, Cl...
$ 3800
Autism Disorder and Treatment- Comprehensive Study by Therapy (Antipsychotic Drugs, Selective Serotonin Reuptake Inhibitors (SSRI) /Antidepressants, Stimulants, Sleep Medications, Others), Type (Auti...
$ 3800
Bone Pain Treatment- Comprehensive Study by Treatment (Therapies, Surgery, Antibiotics, Others), Indication (Injury, Trauma, Bone Tumour, Infection, Others), End User (Hospital, Speciality Clinics, ...
$ 3800
Hemianopsia- Comprehensive Study by Type (Bitemporal, Homonymous, Heteronymous, Superior, Inferior, Others), Treatment (Vision Restoration Therapy (VRT), Visual Field Expander Aid, Visual Auditory Tr...
$ 3800